LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically or cytologically confirmed advanced colon, breast, non-small cell lung, bladder, pancreas, or ovarian cancer refractory to standard treatment or for which no effective standard therapy exists
• •Expresses Lewis Y antigen
• •Evidence of disease progression
• •B3 antigen on the surface of more than 30% of the tumor cells determined by immunohistochemistry
• •No neutralizing antibodies to LMB-9 immunotoxin
• •No untreated CNS metastases
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Sex:
• •Male or female
• •Performance status:
• •ECOG 0-1
• •Life expectancy:
• •At least 3 months
• •Hematopoietic:
• •Absolute granulocyte count greater than 1,200/mm\^3
• •Platelet count greater than 100,000/mm\^3
• •Hepatic:
• •Bilirubin no greater than 1.5 times normal
• •SGOT and SGPT no greater than 2.5 times upper limit of normal (liver metastases allowed)
• •Albumin at least 3.0 g/dL
• •No prior liver disease (e.g., alcohol liver disease)
• •Hepatitis B and C negative
• •Renal:
• •Creatinine no greater than 1.4 mg/dL
• •Creatinine clearance greater than 60 mL/min
• •Proteinuria less than 1 g/24 hours
• •Cardiovascular:
• •No history of coronary artery disease
• •No cardiac arrhythmia requiring therapy
• •No New York Heart Association class II-IV congestive heart failure
• •Pulmonary:
• •Pulmonary function test required if significant smoking history, possible pulmonary disease, or lung cancer
• •FEV1 and FVC at least 65% predicted
• •Other:
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No known seizure disorders
• •No urinary tract infection
• •No other concurrent malignancy
• •No active peptic ulcer disease
• •No known allergy to omeprazole
• •No contraindication to pressor therapy
• •No other concurrent medical or psychological condition that would preclude study
• •PRIOR CONCURRENT THERAPY:
• •Chemotherapy:
• •At least 3 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas) and recovered
• •Endocrine therapy:
• •At least 3 weeks since prior hormonal therapy
• •Radiotherapy:
• •At least 3 weeks since prior radiotherapy and recovered